Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Izokibep in Non-infectious Intermediate, Posterior or Pan-uveitis
2024-514975-16-00Phase 2Completed
- Sponsor
- Acelyrin
- Start
- Aug 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in uveitis comparing Izokibep with Placebo (2 arms). Primary endpoint: Time to treatment failure. Started Aug 2024; status: completed.
02
Drugs
izokibep
03
Conditions
uveitis
Beyond the preview
Go deeper on 2024-514975-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514975-16-00.